Literature DB >> 23059018

Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?

Roy H Perlis1, Rudolf Uher, Nader Perroud, Maurizio Fava.   

Abstract

OBJECTIVE: A subset of patients undergoing initial antidepressant treatment experience worsening of symptoms, including thoughts of suicide or suicidal behavior. The present study explores whether this subset of patients is also more likely to experience recurrence or worsening of these symptoms during a second treatment trial with a different antidepressant.
METHOD: We examined data collected between July 2001 and September 2006 from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a multicenter effectiveness study of outpatients with major depressive disorder diagnosed by a DSM-IV checklist. In that study, subjects who did not remit with citalopram treatment were randomized among next-step treatment options. The main outcome measure for this post hoc analysis, presence of suicidal thoughts and behaviors, was assessed using the suicide item on the 16-item Quick Inventory of Depressive Symptomatology--Self-Rated. Logistic regression was used to examine association between emergence or worsening of these symptoms with the first-step (level 1) citalopram treatment and emergence or worsening with next-step (level 2) pharmacologic or psychosocial treatment, including augmentation with bupropion or buspirone; switch to sertraline, venlafaxine, or bupropion; or addition of or switch to cognitive therapy.
RESULTS: Of 1,240 subjects entering level 2 with a score less than 3 on the suicide item, 102 (8.2%) experienced emergence or worsening of suicidal thoughts or behaviors. Emergence or worsening at level 1 was strongly associated with reemergence or worsening at level 2 (crude OR = 4.00 [95% CI, 2.45-6.51], adjusted OR = 2.95 [95% CI, 1.76-4.96]). Overall magnitude of risk was similar among next-step pharmacologic augmentation versus switching.
CONCLUSIONS: These results suggest that individuals who experience emergence or worsening of suicidal thoughts or behaviors with one antidepressant treatment may warrant closer follow-up during the next-step treatment, as these symptoms may recur regardless of which modality is selected. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23059018      PMCID: PMC3787539          DOI: 10.4088/JCP.12m07777

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

Review 1.  How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors.

Authors:  H C Kraemer; E Stice; A Kazdin; D Offord; D Kupfer
Journal:  Am J Psychiatry       Date:  2001-06       Impact factor: 18.112

Review 2.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

3.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

4.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

5.  Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.

Authors:  Roy H Perlis; Charles M Beasley; James D Wines; Roy N Tamura; Cristina Cusin; Deborah Shear; Jay Amsterdam; Frederick Quitkin; Robert E Strong; Jerrold F Rosenbaum; Maurizio Fava
Journal:  Psychother Psychosom       Date:  2007       Impact factor: 17.659

6.  Two clinical trial designs to examine personalized treatments for psychiatric disorders.

Authors:  Andrew C Leon
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

7.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

8.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Authors:  A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe
Journal:  Control Clin Trials       Date:  2004-02

9.  The Inventory of Depressive Symptomatology (IDS): psychometric properties.

Authors:  A J Rush; C M Gullion; M R Basco; R B Jarrett; M H Trivedi
Journal:  Psychol Med       Date:  1996-05       Impact factor: 7.723

10.  Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Authors:  Roy H Perlis; Shaun Purcell; Maurizio Fava; Jesen Fagerness; A John Rush; Madhukar H Trivedi; Jordan W Smoller
Journal:  Arch Gen Psychiatry       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.